The DOI matches its Crossref record; the references it cites are not checked yet.
Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease
Abstract
Although diabetes is a major cause of chronic kidney disease (CKD), limited data describe the cardiovascular benefit of hydroxymethyl glutaryl CoA reductase inhibitors (statins) in people with both of these conditions. This study sought to determine whether pravastatin reduced the incidence of first or recurrent cardiovascular events in people with non-dialysis-dependent CKD and concomitant diabetes, using data from three randomized trials of pravastatin 40 mg daily versus placebo. CKD was defined by estimated GFR <60 or 60 to 89.9 ml/min per 1.73 m2 with proteinuria. Of 19,737 patients, 4099 (20.8%) had CKD but not diabetes at baseline, 873 (4.4%) had diabetes but not CKD, and 571 (2.9%) had both conditions. The primary composite outcome was time to myocardial infarction, coronary death, or percutaneous/surgical coronary revascularization. Median follow-up was 64 mo. After adjustment for trial and random treatment assignment, the incidence of the primary outcome was lowest in individuals with neither CKD nor diabetes (15.2%), intermediate in individuals with only CKD (18.6%) or only diabetes (21.3%), and highest in individuals with both characteristics (27.0%). Pravastatin reduced the relative likelihood of the primary outcome to a similar extent in subgroups defined by the presence or absence of CKD and diabetes. For example, pravastatin was associated with a significant reduction in the relative risk of the primary outcome by 25% in patients with CKD and concomitant diabetes and by 24% in individuals with neither characteristic. However, the absolute reduction in the risk of the primary outcome as a result of pravastatin use was highest in patients with both CKD and diabetes (6.4%) and lowest in individuals with neither characteristic (3.5%). In conclusion, stage 2 or early stage 3 CKD and diabetes both are associated with higher cardiovascular risk, and pravastatin reduces cardiovascular event rates in people with neither, one, or both characteristics. Given the high absolute benefit of pravastatin in patient with diabetes and stage 2 or early stage 3 CKD, this population in particular should be targeted for widespread use of statins. Additional studies are needed to determine whether these benefits apply to patients with more severe CKD, and recruitment to such studies should be given high priority.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The benefit was most marked in subjects with both CKD and diabetes.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [191]
In the citing paper
“Notably there was also a significant reduction in the risk of all-cause mortality (relative risk 0.81, 95% CI 0.73-0.89).”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [191]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 36 · Cited by 159
Metadata
- Authors
- Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., West, M., Craven, T., & Curhan, G.
- Affiliations
- University of Alberta (CA)
- The University of Sydney (AU)
- The University of Queensland (AU)
- The Alfred Hospital (AU)
- Brigham and Women's Hospital (US)
- Corresponding author
- Tonelli, Marcello
- Packard, Chris
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-12
- Volume
- 16
- Issue
- 12
- Pages
- 3748-3754
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2129575029
- Cited by
- 159
- References
- 36
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 7 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 9 · 2014: 20 · 2013: 9 · 2012: 13
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Wake Forest University
- National Heart Foundation of Australia
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- pravastatin, statins, chronic kidney disease, diabetes mellitus, cardiovascular events, myocardial infarction, coronary revascularization, coronary artery disease, cardiovascular risk, subgroup analysis, proteinuria, estimated glomerular filtration rate, absolute risk reduction, drug repurposing
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Probability, Prognosis, Prevalence, Treatment Outcome, Pravastatin, Age Distribution, Sex Distribution, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2005070779
- The paper
- Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., West, M., Craven, T., & Curhan, G. (2005). Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2005070779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.